JPWO2021172498A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021172498A5
JPWO2021172498A5 JP2022503739A JP2022503739A JPWO2021172498A5 JP WO2021172498 A5 JPWO2021172498 A5 JP WO2021172498A5 JP 2022503739 A JP2022503739 A JP 2022503739A JP 2022503739 A JP2022503739 A JP 2022503739A JP WO2021172498 A5 JPWO2021172498 A5 JP WO2021172498A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022503739A
Other languages
English (en)
Other versions
JPWO2021172498A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/007286 external-priority patent/WO2021172498A1/ja
Publication of JPWO2021172498A1 publication Critical patent/JPWO2021172498A1/ja
Priority to JP2022141656A priority Critical patent/JP7292636B2/ja
Publication of JPWO2021172498A5 publication Critical patent/JPWO2021172498A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 本明細書に記載された発明。
JP2022503739A 2020-02-28 2021-02-26 Pending JPWO2021172498A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022141656A JP7292636B2 (ja) 2020-02-28 2022-09-06 エクソン51のスキッピングを誘導するアンチセンス核酸

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020033483 2020-02-28
PCT/JP2021/007286 WO2021172498A1 (ja) 2020-02-28 2021-02-26 エクソン51のスキッピングを誘導するアンチセンス核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022141656A Division JP7292636B2 (ja) 2020-02-28 2022-09-06 エクソン51のスキッピングを誘導するアンチセンス核酸

Publications (2)

Publication Number Publication Date
JPWO2021172498A1 JPWO2021172498A1 (ja) 2021-09-02
JPWO2021172498A5 true JPWO2021172498A5 (ja) 2024-03-04

Family

ID=77491251

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022503739A Pending JPWO2021172498A1 (ja) 2020-02-28 2021-02-26
JP2022141656A Active JP7292636B2 (ja) 2020-02-28 2022-09-06 エクソン51のスキッピングを誘導するアンチセンス核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022141656A Active JP7292636B2 (ja) 2020-02-28 2022-09-06 エクソン51のスキッピングを誘導するアンチセンス核酸

Country Status (17)

Country Link
US (2) US20230140736A1 (ja)
EP (1) EP4112083A1 (ja)
JP (2) JPWO2021172498A1 (ja)
KR (1) KR20220145865A (ja)
CN (1) CN115210376A (ja)
AU (1) AU2021226089A1 (ja)
BR (1) BR112022017066A2 (ja)
CA (1) CA3173049A1 (ja)
CL (1) CL2022002279A1 (ja)
CO (1) CO2022013685A2 (ja)
EC (1) ECSP22074446A (ja)
IL (1) IL295967A (ja)
MX (1) MX2022010545A (ja)
PE (1) PE20230237A1 (ja)
TW (1) TW202200162A (ja)
WO (1) WO2021172498A1 (ja)
ZA (1) ZA202209294B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
WO1991009033A1 (en) 1989-12-20 1991-06-27 Anti-Gene Development Group Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体,デバイス及び医薬組成物
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
EP1568769A4 (en) 2002-11-25 2008-08-06 Masafumi Matsuo ENA-NUCLEIC ACID MEDICAMENTS THAT CHANGE SPLICING IN THE MRNA PRESETTER
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
SI2735568T1 (en) 2006-05-10 2018-01-31 Sarepta Therapeutics, Inc. Analogues of the oligonucleotide, with cationic links between subunits
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
KR102339196B1 (ko) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
JP6519842B2 (ja) 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
LT3118311T (lt) 2014-03-12 2019-04-10 Nippon Shinyaku Co., Ltd. Priešprasminė nukleorūgštis
US10675356B2 (en) 2015-05-19 2020-06-09 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
SI3331891T1 (sl) 2015-08-05 2022-04-29 Eisai R&D Management Co., Ltd. Postopek priprave v bistvu diastereomerno čistega fosforodiamidatnega oligomera, fosforodiamidatni oligomer izdelan po takem postopku in farmacevtski sestavek, ki vsebuje tak fosforodiamidatni oligomer
TW201722439A (zh) 2015-10-09 2017-07-01 波濤生命科學有限公司 寡核苷酸組合物及其方法
EP3485015A4 (en) * 2016-07-15 2020-07-29 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS OF MODULATION OF DYSTROPHINE TRANSCRIPT
WO2018118599A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
LT3554552T (lt) 2016-12-19 2022-10-10 Sarepta Therapeutics, Inc. Egzoną praleidžiantys oligomerų konjugatai nuo raumenų distrofijos
CN117298290A (zh) 2016-12-19 2023-12-29 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
WO2019241385A2 (en) 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystropy

Similar Documents

Publication Publication Date Title
JP2021151238A5 (ja)
JP2024036694A5 (ja)
JP2021184963A5 (ja)
JP2023105131A5 (ja)
JP2022184985A5 (ja)
JP2020040981A5 (ja)
JP2020007340A5 (ja)
JP2021048879A5 (ja)
JP2020534795A5 (ja)
JP2022185040A5 (ja)
JP2022122972A5 (ja)
JP2021100406A5 (ja)
JPWO2020148954A5 (ja)
JP2024012435A5 (ja)
JP2023181322A5 (ja)
JP2023166402A5 (ja)
JP2020079331A5 (ja)
JP2023052878A5 (ja)
JP2023085489A5 (ja)
JP2022064180A5 (ja)
JP2022060220A5 (ja)
JP2023145479A5 (ja)
JP2020120660A5 (ja)
JP2019081810A5 (ja)
JP2021038235A5 (ja)